ATE356638T1 - Hydrolytisch abbaubare carbamatderivate von polyethylenglykol - Google Patents

Hydrolytisch abbaubare carbamatderivate von polyethylenglykol

Info

Publication number
ATE356638T1
ATE356638T1 AT00984208T AT00984208T ATE356638T1 AT E356638 T1 ATE356638 T1 AT E356638T1 AT 00984208 T AT00984208 T AT 00984208T AT 00984208 T AT00984208 T AT 00984208T AT E356638 T1 ATE356638 T1 AT E356638T1
Authority
AT
Austria
Prior art keywords
derivatives
carbamat
polyethylene glycol
carbamate
hydrolytically degradable
Prior art date
Application number
AT00984208T
Other languages
English (en)
Inventor
Michael David Bentley
Xuan Zhao
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE356638T1 publication Critical patent/ATE356638T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33344—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carbamate group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/71—Monoisocyanates or monoisothiocyanates
    • C08G18/711—Monoisocyanates or monoisothiocyanates containing oxygen in addition to isocyanate oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2210/00—Compositions for preparing hydrogels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/82—Subcellular parts of microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
AT00984208T 1999-12-23 2000-12-08 Hydrolytisch abbaubare carbamatderivate von polyethylenglykol ATE356638T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/469,418 US6413507B1 (en) 1999-12-23 1999-12-23 Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Publications (1)

Publication Number Publication Date
ATE356638T1 true ATE356638T1 (de) 2007-04-15

Family

ID=23863712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984208T ATE356638T1 (de) 1999-12-23 2000-12-08 Hydrolytisch abbaubare carbamatderivate von polyethylenglykol

Country Status (11)

Country Link
US (8) US6413507B1 (de)
EP (1) EP1259262B1 (de)
JP (1) JP5031164B2 (de)
KR (1) KR100748052B1 (de)
AT (1) ATE356638T1 (de)
AU (1) AU782032B2 (de)
CA (1) CA2394716C (de)
DE (1) DE60033969T2 (de)
ES (1) ES2281368T3 (de)
MX (1) MXPA02006220A (de)
WO (1) WO2001047562A2 (de)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
AU782298B2 (en) * 1999-10-04 2005-07-14 Nektar Therapeutics Polymer stabilized neuropeptides
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2002360284B2 (en) 2001-10-18 2006-11-02 Nektar Therapeutics Polymer conjugates of opioid antagonists
JP2005514438A (ja) 2001-12-21 2005-05-19 ソーン， デイビッド エス． 薬剤の可溶化、安定化、及び運搬のためのオリゴマー及びポリマーの使用
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
SE0201874D0 (sv) * 2002-06-19 2002-06-19 Biosensor Applications Sweden Ab Publ Coated metal surface on solid support for displacement reactions
GB0218827D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic compounds and conjugates thereof
AU2003272068A1 (en) * 2002-10-21 2004-05-04 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
EP1581582B2 (de) 2003-01-06 2017-06-07 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
ATE513807T1 (de) * 2003-02-24 2011-07-15 Nrl Pharma Inc Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PL2405015T3 (pl) 2003-03-05 2016-09-30 Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2004089421A2 (en) * 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
AR044926A1 (es) 2003-06-26 2005-10-12 Control Delivery Sys Inc Sistema de suministro de farmacos gelificante in situ
ATE536861T1 (de) 2003-06-26 2011-12-15 Control Delivery Sys Inc Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
US7335751B2 (en) * 2003-08-01 2008-02-26 Biocon Limited Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7534902B2 (en) * 2003-11-14 2009-05-19 Wisconsin Alumni Research Foundation Fluorescence assays with improved sensitivity
CA2758460C (en) 2003-12-16 2014-09-23 Nektar Therapeutics Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
CA2558583C (en) * 2004-03-15 2013-07-09 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors
BRPI0512235A (pt) * 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
US7456151B2 (en) 2004-07-14 2008-11-25 University Of Utah Research Foundation Promoting angiogenesis with netrin1 polypeptides
CA2569381A1 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP4920593B2 (ja) * 2004-10-25 2012-04-18 インテザイン テクノロジーズ， インコーポレイテッド ヘテロ二官能性ポリ（エチレングリコール）およびそれらの使用
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) * 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
AU2006247734B2 (en) 2005-05-13 2011-06-23 Eli Lilly And Company GLP-1 pegylated compounds
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
SG165353A1 (en) 2005-06-03 2010-10-28 Ambrx Inc Improved human interferon molecules and their uses
EP2279758B1 (de) 2005-06-16 2015-02-25 Nektar Therapeutics Konjugate mit abbaubarer Verknüpfung und Polymerreagenzien zur Herstellung dieser Konjugate
WO2006138463A2 (en) * 2005-06-17 2006-12-28 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
MX2008001328A (es) 2005-07-29 2008-04-09 Nektar Therapeutics Al Corp Metodos para preparar esteres de carbonato de poli (etilenglicol).
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CN103030801B (zh) 2006-02-21 2015-07-22 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
EP2010477A4 (de) * 2006-04-27 2012-05-30 Intezyne Technologies Inc Poly (ethylenglykol) mit chemisch ungleichen endgruppen
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8268948B2 (en) * 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
AU2007292903B2 (en) * 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
KR101503085B1 (ko) 2006-12-27 2015-03-16 넥타르 테라퓨틱스 방출가능한 연결을 갖는 폰 빌레브란드 인자­ 및 인자 ⅷ­폴리머 컨주게이트
US8507653B2 (en) * 2006-12-27 2013-08-13 Nektar Therapeutics Factor IX moiety-polymer conjugates having a releasable linkage
RS53948B1 (en) 2007-01-18 2015-08-31 Eli Lilly And Company PEGILATED AMYLOID BETA FAB
WO2008116913A2 (en) * 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
EP2195010A4 (de) * 2007-08-21 2012-03-14 Genzyme Corp Behandlung mit kallikrein-inhibitoren
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
WO2009054916A2 (en) * 2007-10-19 2009-04-30 Nektar Therapeutics Al, Corporation Oligomer conjugates of lidocaine and its derivatives
JP2011503101A (ja) * 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
EP2067494A1 (de) 2007-12-04 2009-06-10 Charité-Universitätsmedizin Berlin Blech oder röhrenförmige Struktur aus elastischem biokompatiblem Material und deren Verwendung
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
KR100968280B1 (ko) * 2008-02-13 2010-07-06 가자마 이엔티 (주) 이비인후과용 의료장치
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2271699A1 (de) * 2008-03-14 2011-01-12 Egen, Inc. Biologisch abbaubare vernetzte verzweigte poly(alkylenimine)
KR20160052812A (ko) 2008-04-14 2016-05-12 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
SI2279007T1 (sl) 2008-04-29 2016-09-30 Ascendis Pharma Growth Disorders Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
US8575102B2 (en) * 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
ES2617868T3 (es) * 2008-08-22 2017-06-20 Baxalta GmbH Derivados de carbonato de bencilo poliméricos
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
EP2350118B1 (de) 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
WO2010033227A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
WO2010033215A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010033221A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
WO2010033217A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
US20110165113A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of v681-like peptides
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2334338A2 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von c-peptiden
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
EP2349341B1 (de) * 2008-10-15 2013-10-09 Baxter Healthcare SA Pegylierung von rekombinanten blutgerinnungsfaktoren in anwesenheit von gebundenen antikörpern
WO2010067378A2 (en) 2008-12-08 2010-06-17 Reliance Life Sciences Pvt. Ltd. Hydrogel composition
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
EP2385843A4 (de) 2009-01-06 2013-02-27 Dyax Corp Behandlung von mukositis mit kallikrein-hemmern
JP5604714B2 (ja) * 2009-02-24 2014-10-15 学校法人立命館 両端アミド型ヒドロゲル化剤
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
KR101759499B1 (ko) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
EP2459228B1 (de) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrug bestehend aus Insulin-Linker-Konjugat
DK2477603T3 (en) 2009-09-17 2016-06-13 Baxalta Inc STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
CN107033368A (zh) 2009-11-09 2017-08-11 聚光灯技术合伙有限责任公司 碎裂水凝胶
HUE038405T2 (hu) 2009-12-15 2018-10-29 Ascendis Pharma Endocrinology Div A/S Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény
EP2805965A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
EP2525831B1 (de) 2010-01-22 2019-05-15 Ascendis Pharma A/S Trägerverknüpfte carbamat-prodrug-linker
WO2011140393A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2595624B1 (de) 2010-07-20 2018-01-31 Halozyme, Inc. Verfahren zur linderung bzw. vermeidung der nebenwirkungen im zusammenhang mit der verabreichung eines anti-hyaluronan-mittels
EA201691292A1 (ru) 2010-07-30 2017-08-31 Баксалта Инкорпорейтид Нуклеофильные катализаторы для оксимного связывания
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EA023929B1 (ru) 2010-09-30 2016-07-29 Астразенека Аб Кристаллический конъюгат налоксол-peg
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
US20120196933A1 (en) * 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2714093A1 (de) 2011-05-27 2014-04-09 Baxter International Inc. Therapeutische proteine mit erhöhter halbwertzeit und verfahren zu ihrer herstellung
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EA201400030A1 (ru) 2011-06-17 2014-07-30 Галозим, Инк. Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012296949B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
MX2014003993A (es) 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
EA030440B1 (ru) 2011-10-24 2018-08-31 Галозим, Инк. Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
RS59703B1 (sr) 2011-12-30 2020-01-31 Halozyme Inc Varijante ph20 polipeptida, njihove formulacije i upotrebe
CA2986512C (en) 2012-04-04 2022-05-17 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
AU2013328774B2 (en) 2012-10-11 2017-11-30 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014148378A1 (ja) * 2013-03-19 2014-09-25 公立大学法人首都大学東京 界面活性剤様化合物
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP2949687B1 (de) 2014-05-29 2016-10-19 Dow Global Technologies Llc Wasserzuführverfahren zur steuerung der molekulargewichtsverteilung und von nebenprodukten der carbamylierung von harnstoff
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
EP3387018A1 (de) 2015-12-11 2018-10-17 Dyax Corp. Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
JP6925579B2 (ja) * 2016-03-31 2021-08-25 日油株式会社 環状ベンジリデンアセタール構造を有する生分解性ヒドロゲル
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
EP3688007A1 (de) 2017-09-27 2020-08-05 The University of York Biokonjugation von polypeptiden
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
EP3849614B1 (de) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
BR112021012601A2 (pt) 2018-12-28 2021-11-30 Catalyst Biosciences Inc Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN114286693A (zh) * 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4199968A1 (de) 2020-08-20 2023-06-28 Ambrx, Inc. Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
CN114209824B (zh) * 2021-11-09 2023-06-20 淮阴工学院 用于肿瘤渗透增强性光热与化疗联合使用的阿霉素前药及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
ES2247656T3 (es) 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US5413992A (en) 1992-07-31 1995-05-09 The Scripps Research Institute Daunomycin derivative with reduced cytotoxicity toward normal cells
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Also Published As

Publication number Publication date
JP5031164B2 (ja) 2012-09-19
WO2001047562A8 (en) 2003-10-23
AU782032B2 (en) 2005-06-30
CA2394716C (en) 2012-02-21
WO2001047562A3 (en) 2002-09-12
US20010046481A1 (en) 2001-11-29
US20060193823A1 (en) 2006-08-31
KR20020074461A (ko) 2002-09-30
EP1259262A1 (de) 2002-11-27
US6461602B2 (en) 2002-10-08
US7060259B2 (en) 2006-06-13
US20040013637A1 (en) 2004-01-22
CA2394716A1 (en) 2001-07-05
AU2086901A (en) 2001-07-09
DE60033969D1 (de) 2007-04-26
US7988956B2 (en) 2011-08-02
ES2281368T3 (es) 2007-10-01
DE60033969T2 (de) 2007-12-20
US20050147583A1 (en) 2005-07-07
EP1259262B1 (de) 2007-03-14
US7608253B2 (en) 2009-10-27
JP2003518526A (ja) 2003-06-10
US20010027212A1 (en) 2001-10-04
US6514491B1 (en) 2003-02-04
KR100748052B1 (ko) 2007-08-09
MXPA02006220A (es) 2002-12-13
US6413507B1 (en) 2002-07-02
US6541015B2 (en) 2003-04-01
US20100105946A1 (en) 2010-04-29
WO2001047562A2 (en) 2001-07-05
US6899867B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
ATE356638T1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
ATE358150T1 (de) Abbaubare polyethyleneglycolhydrogele mit kontrollierter halbwertzeit und ihre vorprodukte
WO2001000246A3 (en) Hydrogels derived from chitosan and poly(ethylene glycol)
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
WO1999029353A3 (en) Medical devices with improved properties
ATE317711T1 (de) Elektropolymerisierbare monomere und polymerbeschichtungen auf implantierbaren geräten
WO2000021572A3 (en) Hydrogels and water soluble polymeric carriers for drug delivery
WO2001049258A3 (en) Methods and compositions for improved delivery devices
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
DK1061900T3 (da) Dermale præparater
WO2003008555A3 (en) Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
AU2001288829A1 (en) Degradable polyacetal polymers
CA2266581A1 (en) Polymers containing polysaccharides such as alginates or modified alginates
CY2603B2 (en) Pharmaceutical compositions
ATE277640T1 (de) Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
EP3449946A3 (de) Hydrophobe kernträgerzusammensetzungen zur verabreichung von therapeutika, verfahren zur herstellung und verwendung davon
WO2006039276A3 (en) Lactam polymer derivatives
AU2003234423A1 (en) Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
TR200400295T2 (tr) Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
NO995925L (no) Farmasoeytiske sammensetninger omfattende cyklodekstriner
HK1093216A1 (en) Cationic polymers having degradable crosslinks
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259262

Country of ref document: EP